Konstantinos N. Lazaridis, M.D.

This study is a biobank of specimens and clinical data for use in current and future research to better understand the cholestatic liver diseases primary biliary cirrhosis/cholangitis (PBC) and primary sclerosing cholangitis (PSC).

The objectives of this study are to establish and perpetuate human biliary cell-derived organoids, to assess genetic and signaling pathway alterations in organoids derived from PSC patients as compared to Non-PSC patients, and to investigate the potential utility of organoids in the in vitro testing of experimental drugs.

The purpose of this study is to better understand disease development of Irritiable Bowel Disease (IBD) and related diseases as a step to improving disease outcomes.

The purpose of this study is to understand and predict biological processes before disease onset, investigate host and environmental contributors to disease, enable early and effective interventions, and develop biologically targeted therapies.

The purpose of this study is to create a resource of data to better understand PBC, PSC, and controls from Mayo Clinic patients and non-Mayo Clinic Patients. Build a repository of information that can be utilized by other researchers. Build a data platform that will allow subjects to easily enter data about themselves, increase our interactions in patients, and help keep patients with PBC and PSC with the most up-to-date information with the CareEvolution platform using the MyDataHelps application.

The purpose of this study is to learn more about how individuals break down and process their medications based on their genes.

The goal of this study is to examine the current and (potential) future therapeutic relevance of PGx testing in established patients with liver disease seen in the Division of Gastroenterology/Hepatology, in order to improve patient clinical care at Mayo Clinic with more effective and efficient prescribing of medications.

The goal of this study is to examine the current and (potential) future therapeutic relevance of pharmacogenomics (PGx) testing for a group of patients in order to improve patient clinical care at Mayo Clinic with more effective and efficient prescribing of medications.

The overall objective of this proposal is to conduct a systematic approach to dissect both genetic underpinnings and non-genetic factors in the development of adult autoimmune liver diseases including autoimmune hepatitis (AIH), overlap AIH with Primary Biliary Cirrhosis (AIH-PBC), overlap AIH with Primary Sclerosing Cholangitis (AIH-PSC), and drug-induced autoimmune-like hepatitis (DIAIH).

The purpose of this study is to prospectively collect longitudinal stool specimens and corresponding clinical and patient provided data from asymptomatic patients or those with history of exposure or patients presenting with symptoms suggestive of COVID-19 who are undergoing testing for the novel SARS-CoV-2 virus to enable high quality research.

The goals of this study are to collect and store biospecimens (e.g., blood, urine, saliva, stool) in order to support future research. These biospecimens will be tested and used to better understand why a disease or disorder occurs and how it progresses over time. This knowledge could aid future patients.

The purpose of this study is to better understand the impact of predictive genomic testing in the healthy adult population by assessing decisional satisfaction/regret, understanding of disease risk, lifestyle modifications, and satisfaction with the testing experience. 

The purpose of this study is to evaluate the proposed risks and benefits of predictive genomic sequencing, including short-and long-term impacts on:

(i) health-related outcomes;
(ii) healthcare utilization;
(iii) psychosocial impact, and
(iv) physician acceptance.

The purpose of this study is to test new technology called Next Generation Sequencing (NGS) that may help identify possible useful genetic information for your clinical care. NGS is a procedure that looks at all of your genes (the genetic material you have inherited from your parents). In this study, we want to collect detailed family history of enrolled patients, when available through an electronic-based, pedigree tool, identify exomic variants in patients using whole exome sequencing, understand how patients use the results of the genomic sequencing, and create a data repository of clinical phenotypes of patients linked to their genomic variant.

We may conduct additional research on the information using various computational programs to better understand the genetic changes being reported. We also want to store samples and genetic information for future research using further tests to determine the clinical significance of genetic variants identified during the genomic testing process.